BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1385479)

  • 21. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement regulatory proteins in glomerular diseases.
    Nangaku M
    Kidney Int; 1998 Nov; 54(5):1419-28. PubMed ID: 9844117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2.
    Molina H; Kinoshita T; Webster CB; Holers VM
    J Immunol; 1994 Jul; 153(2):789-95. PubMed ID: 8021513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).
    Marquart HV; Grønbaek K; Christensen BE; Svehag SE; Leslie RG
    Clin Exp Immunol; 1995 Dec; 102(3):575-81. PubMed ID: 8536375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
    Leslie RG; Prodinger WM; Nielsen CH
    Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement regulatory proteins in early human fetal life: CD59, membrane co-factor protein (MCP) and decay-accelerating factor (DAF) are differentially expressed in the developing liver.
    Simpson KL; Houlihan JM; Holmes CH
    Immunology; 1993 Oct; 80(2):183-90. PubMed ID: 7505254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
    Delibrias CC; Fischer E; Bismuth G; Kazatchkine MD
    J Immunol; 1992 Aug; 149(3):768-74. PubMed ID: 1386093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
    Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
    J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
    Fischer E; Appay MD; Cook J; Kazatchkine MD
    J Immunol; 1986 Feb; 136(4):1373-7. PubMed ID: 2418113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Complement regulatory factors and immunologic recognition mechanism between species].
    Seya T; Matsunoto M
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):637-42. PubMed ID: 8963770
    [No Abstract]   [Full Text] [Related]  

  • 31. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells.
    Kozono Y; Abe R; Kozono H; Kelly RG; Azuma T; Holers VM
    J Immunol; 1998 Feb; 160(4):1565-72. PubMed ID: 9469411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement deposits in epidermal cells after ultraviolet B exposure.
    Rauterberg A; Jung EG; Rauterberg EW
    Photodermatol Photoimmunol Photomed; 1993 Aug; 9(4):135-43. PubMed ID: 8318429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complement regulatory proteins and autoimmunity.
    Kawano M
    Arch Immunol Ther Exp (Warsz); 2000; 48(5):367-72. PubMed ID: 11140463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure and signalling functions of C3 receptors on human B cells.
    Frade R
    Semin Immunol; 1990 Mar; 2(2):159-64. PubMed ID: 2151800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract.
    Varsano S; Frolkis I; Ophir D
    Am J Respir Crit Care Med; 1995 Sep; 152(3):1087-93. PubMed ID: 7545058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21).
    Kazatchkine MD; Fearon DT
    Immunodefic Rev; 1990; 2(1):17-41. PubMed ID: 2164822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.